The global market for Severe Hypertriglyceridemia (SHTG) Therapeutics was estimated to be worth US$ 614 million in 2023 and is forecast to a readjusted size of US$ 1567.5 million by 2030 with a CAGR of 14.3% during the forecast period 2024-2030

Severe Hypertriglyceridemia (SHTG) Therapeutics - Market

Severe Hypertriglyceridemia (SHTG) is a medical condition characterized by abnormally high levels of triglycerides in the blood, which can lead to the development of cardiovascular diseases. SHTG is a serious condition that requires prompt treatment to reduce the risk of cardiovascular events such as heart attacks and strokes.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Severe Hypertriglyceridemia (SHTG) Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Severe Hypertriglyceridemia (SHTG) Therapeutics by region & country, by Type, and by Application.

The Severe Hypertriglyceridemia (SHTG) Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Severe Hypertriglyceridemia (SHTG) Therapeutics.

Market Segmentation

Scope of Severe Hypertriglyceridemia (SHTG) Therapeutics - Market Report

Report Metric	Details
Report Name	Severe Hypertriglyceridemia (SHTG) Therapeutics - Market
Forecasted market size in 2030	US$ 1567.5 million
CAGR	14.3%
Forecasted years	2024 - 2030
Segment by Type:	Oral Intravenous Injection
Segment by Application	Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., NorthSea Therapeutics B.V., Amryt Pharma, Afimmune Pharmaceutical, Zucara Therapeutics, Novo Nordisk, Adocia, Pfizer Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Severe Hypertriglyceridemia (SHTG) Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Severe Hypertriglyceridemia (SHTG) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Severe Hypertriglyceridemia (SHTG) Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Severe Hypertriglyceridemia (SHTG) Therapeutics - Market size in 2030?

Ans: The Severe Hypertriglyceridemia (SHTG) Therapeutics - Market size in 2030 will be US$ 1567.5 million.

Who are the main players in the Severe Hypertriglyceridemia (SHTG) Therapeutics - Market report?

Ans: The main players in the Severe Hypertriglyceridemia (SHTG) Therapeutics - Market are Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., NorthSea Therapeutics B.V., Amryt Pharma, Afimmune Pharmaceutical, Zucara Therapeutics, Novo Nordisk, Adocia, Pfizer Inc.

What are the Application segmentation covered in the Severe Hypertriglyceridemia (SHTG) Therapeutics - Market report?

Ans: The Applications covered in the Severe Hypertriglyceridemia (SHTG) Therapeutics - Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Severe Hypertriglyceridemia (SHTG) Therapeutics - Market report?

Ans: The Types covered in the Severe Hypertriglyceridemia (SHTG) Therapeutics - Market report are Oral, Intravenous Injection

1 Market Overview

1.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Product Introduction

1.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size Forecast

1.3 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Trends & Drivers

1.3.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Industry Trends

1.3.2 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Drivers & Opportunity

1.3.3 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Challenges

1.3.4 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Players Revenue Ranking (2023)

2.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies Severe Hypertriglyceridemia (SHTG) Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Severe Hypertriglyceridemia (SHTG) Therapeutics

2.6 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Competitive Analysis

2.6.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Severe Hypertriglyceridemia (SHTG) Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Oral

3.1.2 Intravenous Injection

3.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type

3.2.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacy

4.1.2 Retail Pharmacy

4.1.3 Online Pharmacy

4.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application

4.2.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region

5.1.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

5.2.2 North America Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

5.3.2 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

5.5.2 South America Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value

6.3 United States

6.3.1 United States Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

6.3.2 United States Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

6.4.2 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

6.5.2 China Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

6.6.2 Japan Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

6.7.2 South Korea Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019-2030

6.9.2 India Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Ionis Pharmaceuticals

7.1.1 Ionis Pharmaceuticals Profile

7.1.2 Ionis Pharmaceuticals Main Business

7.1.3 Ionis Pharmaceuticals Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.1.4 Ionis Pharmaceuticals Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 Ionis Pharmaceuticals Recent Developments

7.2 89bio, Inc.

7.2.1 89bio, Inc. Profile

7.2.2 89bio, Inc. Main Business

7.2.3 89bio, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.2.4 89bio, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 89bio, Inc. Recent Developments

7.3 Arrowhead Pharmaceuticals, Inc.

7.3.1 Arrowhead Pharmaceuticals, Inc. Profile

7.3.2 Arrowhead Pharmaceuticals, Inc. Main Business

7.3.3 Arrowhead Pharmaceuticals, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.3.4 Arrowhead Pharmaceuticals, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 NorthSea Therapeutics B.V. Recent Developments

7.4 NorthSea Therapeutics B.V.

7.4.1 NorthSea Therapeutics B.V. Profile

7.4.2 NorthSea Therapeutics B.V. Main Business

7.4.3 NorthSea Therapeutics B.V. Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.4.4 NorthSea Therapeutics B.V. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 NorthSea Therapeutics B.V. Recent Developments

7.5 Amryt Pharma

7.5.1 Amryt Pharma Profile

7.5.2 Amryt Pharma Main Business

7.5.3 Amryt Pharma Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.5.4 Amryt Pharma Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 Amryt Pharma Recent Developments

7.6 Afimmune Pharmaceutical

7.6.1 Afimmune Pharmaceutical Profile

7.6.2 Afimmune Pharmaceutical Main Business

7.6.3 Afimmune Pharmaceutical Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.6.4 Afimmune Pharmaceutical Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.6.5 Afimmune Pharmaceutical Recent Developments

7.7 Zucara Therapeutics

7.7.1 Zucara Therapeutics Profile

7.7.2 Zucara Therapeutics Main Business

7.7.3 Zucara Therapeutics Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.7.4 Zucara Therapeutics Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.7.5 Zucara Therapeutics Recent Developments

7.8 Novo Nordisk

7.8.1 Novo Nordisk Profile

7.8.2 Novo Nordisk Main Business

7.8.3 Novo Nordisk Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.8.4 Novo Nordisk Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.8.5 Novo Nordisk Recent Developments

7.9 Adocia

7.9.1 Adocia Profile

7.9.2 Adocia Main Business

7.9.3 Adocia Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.9.4 Adocia Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.9.5 Adocia Recent Developments

7.10 Pfizer Inc.

7.10.1 Pfizer Inc. Profile

7.10.2 Pfizer Inc. Main Business

7.10.3 Pfizer Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

7.10.4 Pfizer Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue (US$ Million) & (2019-2024)

7.10.5 Pfizer Inc. Recent Developments

8 Industry Chain Analysis

8.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Industrial Chain

8.2 Severe Hypertriglyceridemia (SHTG) Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Severe Hypertriglyceridemia (SHTG) Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Ionis Pharmaceuticals

89bio Inc

Arrowhead Pharmaceuticals, Inc.

Amryt Pharma

Afimmune Pharmaceutical

NorthSea Therapeutics B.V.

List of Tables

Table 1. Severe Hypertriglyceridemia (SHTG) Therapeutics Market Trends

Table 2. Severe Hypertriglyceridemia (SHTG) Therapeutics Market Drivers & Opportunity

Table 3. Severe Hypertriglyceridemia (SHTG) Therapeutics Market Challenges

Table 4. Severe Hypertriglyceridemia (SHTG) Therapeutics Market Restraints

Table 5. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Severe Hypertriglyceridemia (SHTG) Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Severe Hypertriglyceridemia (SHTG) Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Severe Hypertriglyceridemia (SHTG) Therapeutics

Table 10. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Severe Hypertriglyceridemia (SHTG) Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. Ionis Pharmaceuticals Basic Information List

Table 32. Ionis Pharmaceuticals Description and Business Overview

Table 33. Ionis Pharmaceuticals Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of Ionis Pharmaceuticals (2019-2024)

Table 35. Ionis Pharmaceuticals Recent Developments

Table 36. 89bio, Inc. Basic Information List

Table 37. 89bio, Inc. Description and Business Overview

Table 38. 89bio, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of 89bio, Inc. (2019-2024)

Table 40. 89bio, Inc. Recent Developments

Table 41. Arrowhead Pharmaceuticals, Inc. Basic Information List

Table 42. Arrowhead Pharmaceuticals, Inc. Description and Business Overview

Table 43. Arrowhead Pharmaceuticals, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of Arrowhead Pharmaceuticals, Inc. (2019-2024)

Table 45. Arrowhead Pharmaceuticals, Inc. Recent Developments

Table 46. NorthSea Therapeutics B.V. Basic Information List

Table 47. NorthSea Therapeutics B.V. Description and Business Overview

Table 48. NorthSea Therapeutics B.V. Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of NorthSea Therapeutics B.V. (2019-2024)

Table 50. NorthSea Therapeutics B.V. Recent Developments

Table 51. Amryt Pharma Basic Information List

Table 52. Amryt Pharma Description and Business Overview

Table 53. Amryt Pharma Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of Amryt Pharma (2019-2024)

Table 55. Amryt Pharma Recent Developments

Table 56. Afimmune Pharmaceutical Basic Information List

Table 57. Afimmune Pharmaceutical Description and Business Overview

Table 58. Afimmune Pharmaceutical Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of Afimmune Pharmaceutical (2019-2024)

Table 60. Afimmune Pharmaceutical Recent Developments

Table 61. Zucara Therapeutics Basic Information List

Table 62. Zucara Therapeutics Description and Business Overview

Table 63. Zucara Therapeutics Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of Zucara Therapeutics (2019-2024)

Table 65. Zucara Therapeutics Recent Developments

Table 66. Novo Nordisk Basic Information List

Table 67. Novo Nordisk Description and Business Overview

Table 68. Novo Nordisk Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of Novo Nordisk (2019-2024)

Table 70. Novo Nordisk Recent Developments

Table 71. Adocia Basic Information List

Table 72. Adocia Description and Business Overview

Table 73. Adocia Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of Adocia (2019-2024)

Table 75. Adocia Recent Developments

Table 76. Pfizer Inc. Basic Information List

Table 77. Pfizer Inc. Description and Business Overview

Table 78. Pfizer Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Severe Hypertriglyceridemia (SHTG) Therapeutics Business of Pfizer Inc. (2019-2024)

Table 80. Pfizer Inc. Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Severe Hypertriglyceridemia (SHTG) Therapeutics Downstream Customers

Table 84. Severe Hypertriglyceridemia (SHTG) Therapeutics Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Severe Hypertriglyceridemia (SHTG) Therapeutics Product Picture

Figure 2. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. Severe Hypertriglyceridemia (SHTG) Therapeutics Report Years Considered

Figure 5. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue in 2023

Figure 7. Severe Hypertriglyceridemia (SHTG) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Oral Picture

Figure 9. Intravenous Injection Picture

Figure 10. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospital Pharmacy

Figure 13. Product Picture of Retail Pharmacy

Figure 14. Product Picture of Online Pharmacy

Figure 15. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value (%), (2019-2030)

Figure 28. United States Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 34. China Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 36. China Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 46. India Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 48. India Severe Hypertriglyceridemia (SHTG) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 49. Severe Hypertriglyceridemia (SHTG) Therapeutics Industrial Chain

Figure 50. Severe Hypertriglyceridemia (SHTG) Therapeutics Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions